OncoGenex Announces That The Borealis-2(TM) Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment

The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) have announced initiation of the Borealis-2™ clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy treatment...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Urology / Nephrology Source Type: news